Sarecycline Seysara denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sarecycline seysara are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Sarecycline (Seysara) as Not FDA-Approved

A "not FDA-approved" denial for sarecycline is almost certainly an administrative or coding error. Sarecycline (brand name Seysara) holds a current FDA approval for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in adults and adolescents. If BCBS has issued this denial, the most likely explanations are: a reviewer or automated system applied an incorrect drug code, queried an outdated database, or confused sarecycline with an off-label or compounded product. This class of denial has among the highest overturn rates on appeal.

### Why This Denial Is Appealable

Federal and state insurance law, as well as BCBS's own coverage policies, do not permit denial of coverage for a drug solely on the basis of lacking FDA approval when a current FDA approval exists and the drug is prescribed within that approved indication. Providing objective documentation of the FDA approval is the core of this appeal.

### Federal Appeal Framework

• Internal appeal: File immediately under ERISA §503 (employer plans) or ACA §2719 (individual/small-group plans). Given that this denial is likely an administrative error, a peer-to-peer call from your prescriber can sometimes resolve it without a formal appeal.
• External review: Available after an adverse internal decision under ACA §2719; the external review window is typically around four months from the final internal denial.
• Expedited option: Request expedited review if ongoing lack of medication is causing clinical harm.

### Concrete Appeal Steps

1. Download the FDA-approved prescribing information (package insert) for sarecycline from the FDA's Drugs@FDA database — this is your primary evidence document. 2. Confirm that the drug code (NDC or J-code) on the claim matches sarecycline, not another product. 3. Ask your pharmacy to verify the NDC submitted and correct any coding errors before resubmitting. 4. If a resubmission does not resolve the issue, file a formal internal appeal attaching the FDA label as Exhibit A. 5. Your prescriber's cover letter should state the FDA approval date, the approved indication, and that the prescription is on-label.

### Documentation to Gather

• FDA approval documentation: Printout of the FDA prescribing label or a direct reference to the FDA approval, confirming the indication and approval status.
• Correct claim coding: Pharmacy claim detail confirming the NDC matches sarecycline.
• On-label use confirmation: Prescriber chart note and letter confirming the prescription is for the FDA-approved indication.
• Diagnosis documentation: Chart notes confirming acne vulgaris diagnosis.
• Criteria mapping: Copy the denial language from BCBS's letter; cite the FDA label to refute each stated reason.

### Key Reminder

If BCBS's denial letter cites a specific policy number or reason code, note it exactly and ask BCBS to identify which element of the FDA-approval requirement it believes is unmet. That forces a specific response and often reveals the administrative error quickly.